Overview

Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy

Status:
Not yet recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
The main purpose is to determine whether FPC, administered via infusion, is safe and effective for the treatment of iron deficiency anemia (IDA) in patients receiving Home Infusion therapies (HI).
Phase:
Phase 2
Details
Lead Sponsor:
Rockwell Medical Technologies, Inc.